BioNTech (BNTX) Q4 2025 earnings summary

Executive summary

• Achieved strong COVID-19 vaccine market leadership with over 50% share in key markets, launched a variant-adapted vaccine, and maintained leadership while advancing a diversified oncology pipeline with late-stage assets and novel combinations, including pivotal programs in lung and breast cancer.

• Advanced over 25 phase 2 & 3 oncology trials and 10 novel-combination trials, with strategic partnerships and acquisitions, and sharpened focus on late-stage oncology and next-generation mRNA innovations; CEO and CMO transitions planned by end of 2026.

• Ended 2025 with €17.2 billion in cash, cash equivalents, and securities, supporting a robust pipeline and future launches.

• Announced the creation of a new independent company for next-generation mRNA innovations, with founders transitioning by end of 2026; BioNTech to retain a minority stake and strategic collaboration opportunities.

• Strategic partnerships, notably with BMS, and acquisitions of Biotheus and CureVac, strengthened the pipeline and de-risked key programs.

Financial highlights

• FY 2025 revenues reached €2.87 billion, exceeding guidance (€2.6–2.8 billion), with Q4 2025 revenues at €907 million, down from €1.19 billion in Q4 2024.

• FY 2025 IFRS net loss was €1.14 billion; adjusted net loss was €117 million.

• R&D expenses for 2025 were €2.10 billion (adjusted: €2.02 billion), slightly lower than prior year due to portfolio management and BMS cost-sharing.

• Ended 2025 with €17.2 billion in cash and securities, supporting continued investment in late-stage programs.

• Other operating result for 2025: negative €903.7 million, mainly due to settlements, pipeline prioritization, and FX differences.

Outlook and guidance

• FY 2026 revenue guidance: €2.0–2.3 billion, reflecting lower COVID-19 vaccine sales in US and Europe, partially offset by continued BMS collaboration payments.

• Adjusted R&D expenses for 2026 projected at €2.2–2.5 billion, with increased investment in late-stage oncology and reduced spend outside priority areas.

• SG&A expenses expected at €700–800 million, driven by commercial build-out for oncology launches.

• Multiple late-stage oncology trial readouts and pivotal trial initiations expected in 2026.

• No material short- or mid-term financial impact expected from the new mRNA company transaction.